Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2021 | $8.00 | Neutral → Buy | HC Wainwright & Co. |
| 9/30/2021 | $8.00 → $7.00 | Neutral | HC Wainwright & Co. |
Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF). Under the agreement, Seal Rock Therapeutic
Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten
6-K - Genfit S.A. (0001757064) (Filer)
6-K - Genfit S.A. (0001757064) (Filer)
6-K - Genfit S.A. (0001757064) (Filer)
Ipsen SA (OTC:IPSEF) (OTC:IPSEY) announced Monday that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets to treat primary biliary cholangitis (PBC). PBC is a rare, autoimmune, cholestatic liver disease where a build-up of bile and toxins and chronic inflammation causes irreversible fibrosis of the liver and destruction of the bile ducts. This drug is approved for use with ursodeoxycholic acid (UDCA) or as a standalone treatment in cases where UDCA is not tolerated. Iqirvo is a first-in-class oral, once-daily peroxisome proliferator-activated receptor (PPAR) agonist. Iqirvo was in-licensed from GENFIT S.A. (NASDAQ:GNFT
HC Wainwright & Co. analyst Ed Arce maintains Genfit (NASDAQ:GNFT) with a Buy and raises the price target from $11 to $13.
SC 13G/A - Genfit S.A. (0001757064) (Subject)
SC 13G - Genfit S.A. (0001757064) (Subject)
SC 13G/A - Genfit S.A. (0001757064) (Subject)
Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten
HC Wainwright & Co. upgraded Genfit from Neutral to Buy and set a new price target of $8.00
HC Wainwright & Co. reiterated coverage of Genfit with a rating of Neutral and set a new price target of $7.00 from $8.00 previously
SVB Leerink reiterated coverage of Genfit with a rating of Outperform and set a new price target of $15.00 from $20.00 previously